People · Operator
Named in public records as an officer, director or promoter · active 2012–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Synlogic, Inc. | — | Biotechnology | Series C | $186.5M | $3.3B | 2015 |
| CytomX Therapeutics, Inc. | — | Biotechnology | Series C | $143.0M | $392.5M | 2023 |
| Mersana Therapeutics Inc | — | Biotechnology | Series B | $93.7M | $1.3B | 2015 |
| Blade Therapeutics, Inc. | — | Biotechnology | Series B | $77.0M | $475.5M | 2016 |
| Flexion Therapeutics Inc | — | Biotechnology | Series B | $40.0M | $793.8M | 2012 |
| Aquinox Pharmaceuticals (Usa) Inc | — | Pharmaceuticals | Series A | $30.6M | $433.6M | 2013 |
Elaine Jones at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Elaine Jones on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Elaine V. Jones | 2 | 3 |
| ELAINE J. JONES | 2 | 2 |
| Peter Barrett | 1 | 18 |
| Asish Xavier | 1 | 18 |
| Andrew Schwab | 1 | 16 |
| Michael Powell | 1 | 14 |
| Corey Goodman | 1 | 13 |
| Luke Evnin | 1 | 12 |
| Edward Mathers | 1 | 12 |
| Ed Mathers | 1 | 11 |
| BRADLEY BOLZON | 1 | 10 |
| Heath Lukatch | 1 | 10 |
| Cameron Wheeler | 1 | 9 |
| Chau Khuong | 1 | 9 |
| David Mott | 1 | 9 |
| Matthew Young | 1 | 7 |
| Thomas Beck | 1 | 7 |
| Daniel Geffken | 1 | 6 |
| Kenneth Galbraith | 1 | 6 |
| Lewis Geffen | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.